Aspire-Lakewood Holdings, Inc.
ASBP Healthcare Biotechnology
Aspire-Lakewood Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6,200.00. In the quarter to June 2026, EPS grew 97.5%, free cash flow fell 85.5% and total debt fell 79.7%, each against the same quarter a year earlier.
Follow ASBP
Aspire-Lakewood Holdings, Inc. (ASBP) P/E ratio
As of 16 October 2026, Aspire-Lakewood Holdings, Inc. (ASBP) trades at a P/E ratio of 0.2×. Over the past ten years it has ranged from 0.0× (June 2026) to 187× (September 2022); the current reading is higher than 46% of that period. That is below the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.1× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ACTU Actuate Therapeutics, Inc. compare | n/m |
| CTXR Citius Pharmaceuticals, Inc. compare | n/m |
| AEON AEON Biopharma, Inc. compare | n/m |
| PLUR Pluri Inc. compare | n/m |
| ENSC Ensysce Biosciences, Inc. compare | n/m |
| INAB IN8bio, Inc. compare | n/m |
| PASG Passage Bio, Inc. compare | n/m |
| CASIF CASI Pharmaceuticals Inc. compare | n/m |
| ASBP Aspire-Lakewood Holdings, Inc. | 0.2× |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)